Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

IRADIMED CORP Director's Dealing 2022

Dec 9, 2022

32324_dirs_2022-12-09_521b257a-0e22-4a85-919b-20f39d69d5f0.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: IRADIMED CORP (IRMD)
CIK: 0001325618
Period of Report: 2022-12-07

Reporting Person: GLENN JOHN (N/A)

Derivative Transactions

Date Security Exercise Price Code Shares A/D Expiration Underlying Ownership
2022-12-07 Restricted Stock Units $ A 10504 Acquired Common Stock (10504) Direct
2022-12-07 Performance-based Restricted Stock Units $ A 10504 Acquired Common Stock (10504) Direct

Footnotes

F1: Each restricted stock unit represents a contingent right to receive one share of Iradimed Corporation's common stock.

F2: The reporting person received restricted stock units under Iradimed Corporation's 2014 Equity Incentive Plan. The restricted stock units vest in full on the third anniversary of the grant date, December 7, 2025. Upon vesting, the reporting person will receive a number of shares of common stock equal to the number of restricted stock units that have vested.

F3: The reporting person received performance-based restricted stock units ("PRSUs") under Iradimed Corporation's 2014 Equity Incentive Plan. Vesting of these PRSUs depends on the reporting person's achievement of a specified relative ranking of total stockholder return over a three-year period from December 8, 2022 through December 7, 2025.

F4: If the relative measure at December 7, 2025 and for the three-year period then ended is: (i) less than or equal to 80% of the peer group, no vesting would occur, (ii) between 80% and 100% of the peer group, the number of shares vesting would be pro-rata against the nominal granted shares, (iii) equal to 100% of the peer group, the number of shares vesting would be the nominal granted shares, (iv) between 100% and 120% of the peer group, the number of shares vesting would be pro-rata against an additional tranche of the nominal granted shares plus the nominal granted shares, and (v) if 120% or greater of the peer group, the number of shares vesting would be double the nominal granted shares.

F5: Upon vesting, the reporting person will receive a number of shares of common stock equal to the number of PRSUs that have vested.